



**Associazione Italiana di Neuro-Oncologia**

---

## **Case discussion**

**A case of BRAF mutated glioblastoma  
but handle with care!**

***V. Polo***

***UOC Oncologia - Treviso***


REGIONE DEL VENETO



**ULSS2**  
MARCA TREVIGIANA

## A case of **BRAF mutated glioblastoma** but handle with care!



- Maschio, 42 anni, nessuna comorbidità
- Cefalea persistente e sindrome vertiginosa: riscontro di lesione cistica paraventricolare dx



- 26/03/2019 sottoposto a resezione subtotale
- **Glioblastoma epitelioide, IDH wt, MGMT non metilato, BRAF V600E mutato**
- 05/2019 – 12/2019 Protocollo Stupp


# A case of **BRAF mutated glioblastoma** but handle with care!

- 12/2020 Aumento di volume del noto nodulo



- 12/2020 Terapia con Dabrafenib 150 mg x 2/die
- Riduzione dei reperti alle successive RM (criteri RANO: SD)


**01/2022**




# A case of **BRAF mutated glioblastoma** but handle with care!

- 05/2022 Lieve incremento dimensionale del noto nodulo
- Prosegue Dabrafenib monoterapia
- 10/2022 Ulteriore lieve progressione

01/2022




10/2022



- 10/2022 Associazione Dabrafenib + Trametinib 2 mg/die

# A case of **BRAF mutated glioblastoma** but handle with care!

- 01/2023 Ulteriore progressione di malattia



- 21/03/2023 Asportazione radicale del nodulo di malattia
- **Glioblastoma IDH wt, BRAF V600E mutato**
- 04/2023 RM post-operatoria: no residuo
- 05/2023 Terapia con Temodal



# A case of **BRAF mutated glioblastoma** but handle with care!

## Available clinical data on BRAF V600E mutated GBM treated with BRAF inhibitors alone or in combination

Author	Drug	Study type	Tumor type	N. patients	Best Response
Robinson et al. (57)	vemurafenib	case report	V600E GBM	1	CR
Burger et al. (53)	dabrafenib	case report	V600E GBM	1	CR
Ceccon et al. (54)	dabrafenib	case report	V600E eGBM	1	SD
Qin C et al. (58)	dabrafenib	case report	V600E GBM	1	PR
Beba et al. (52)	vemurafenib	case report	V600E GBM	1	SD
Schreck et al. (59)	dabrafenib + trametinib	case report	V600E eGBM	1	SD
Kushnirsky et al. (60)	dabrafenib + trametinib	case report	V600E GBM	1	CR
Kanemaru et al. (61)	dabrafenib + trametinib	case report	V600E eGBM	1	PR
Johanns et al. (55)	dabrafenib + trametinib	case report	V600E eGBM	1	PR
Kaley et al. (56)	vemurafenib	basket trial	V600E GBM	11	ORR 11%
Wen et al. (62)	dabrafenib + trametinib	basket trial	V600E GBM	31	ORR 33%


# A case of BRAF mutated glioblastoma but handle with care!

## BRAF Inhibition in $BRAF^{V600}$ -Mutant Gliomas: Results From the VE-BASKET Study



# A case of BRAF mutated glioblastoma but handle with care!

Dabrafenib plus trametinib in patients with  $BRAF^{V600E}$ -mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial



- High grade glioma: 45 patients
- 28 patients had received two or more previous antineoplastic regimens
- GBM: 31 patients
- GBM: mPFS 2.8 m; mOS 13.7 m

## High-grade glioma cohort (n=45)

	Investigator-assessed (n=45)	Investigator-assessed grade III only (n=13)*	Investigator-assessed glioblastoma only (n=31)*	Independent radiology review (n=45)
<b>Best response</b>				
Complete response	3 (7%)	1 (8%)	2 (6%)	3 (7%)
Partial response	12 (27%)	4 (31%)	8 (26%)	11 (24%)
Minor response	..	..	..	..
Stable disease	10 (22%)	3 (23%)	6 (19%)	5 (11%)
Progressive disease	19 (42%)	5 (38%)	14 (45%)	20 (44%)
Not evaluable	1 (2%)	0	1 (3%)	6 (13%)
Objective response rate (complete response plus partial response)	15 (33%; 20-49)	5 (38%; 14-68)	10 (32%; 17-51)	14 (31%; 18-47)



# A case of **BRAF** mutated glioblastoma but handle with care!

<b>ONCOGENE-ADDICTED TUMORS</b>	<b>BRAF<sup>V600E</sup> MUTANT GLIOBLASTOMA</b>
Upfront targeted therapy	
Therapy beyond progression	
Targeted therapy + local therapy	
Acquired resistance	
Rebiopsy	



- **Discussione neuroncologo – oncologo**
- **Discussione multidisciplinare**



Associazione Italiana di Neuro-Oncologia

---

***GRAZIE***

***V. Polo***

***UOC Oncologia - Treviso***

REGIONE DEL VENETO



**ULSS2**  
MARCA TREVIGIANA